- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||cabiralizumab|
|Search PubMed titles||cabiralizumab|
|Search PubMed titles/abstracts||cabiralizumab|
|Cabiralizumab is an investigational humanized monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is being investigated for its potential anti-cancer activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US20110274683